Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

2.220 +0.160 (+7.77%)

Streaming Delayed Price Updated: 11:31 AM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

December 24, 2022

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket ↗

December 23, 2022

Gainers Expion360 Inc. (NASDAQ: XPON) shares rose 152% to $2.47 in pre-market trading. Expion360 been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer...

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Looking Into Coherus BioSciences Return On Capital Employed ↗

August 17, 2022

Via Benzinga

Recap: Coherus BioSciences Q1 Earnings ↗

May 05, 2022

Coherus BioSciences (NASDAQ:CHRS) reported its Q1 earnings results on Thursday, May 5, 2022 at 05:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

November 08, 2022

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus BioSciences Earnings Preview ↗

November 07, 2022

Coherus BioSciences (NASDAQ:CHRS) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Coherus...

Via Benzinga

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

November 01, 2022

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical

October 12, 2022

From Coherus BioSciences, Inc.; Shanghai Junshi Biosciences Co., Ltd

Via GlobeNewswire

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer ↗

May 02, 2022

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.

Via Benzinga

Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting ↗

March 15, 2022

Via Benzinga

Recap: Coherus BioSciences Q4 Earnings ↗

February 17, 2022

Coherus BioSciences (NASDAQ:CHRS) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Coherus's Refiling For Head and Neck Cancer Candidate Accepted By FDA For Review ↗

July 06, 2022

Coherus BioSciences (NASDAQ: CHRS) announced that the United States Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for Toripalimab in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops ↗

May 14, 2022

Zhaoke Ophthalmology acquired China/Southeast Asia rights for two eyedrop candidates from Visus Therapeutics in a $130 million deal. Meanwhile, Coherus Biosciences returned the US rights to market an...

Via Talk Markets

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗

May 13, 2022

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund ↗

May 07, 2022

One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in...

Via Talk Markets

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Outlook For Coherus BioSciences ↗

May 04, 2022

Coherus BioSciences (NASDAQ:CHRS) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Coherus...

Via Benzinga

Coherus and Junshi Biosciences Receive CRL from FDA for Toripalimab in combination with Gemcitabine and Cisplatin In metastatic nasopharyngeal carcinoma (NPC) ↗

May 02, 2022

Shanghai Junshi Biosciences and Coherus BioSciences, Inc. (NASDAQ: CHRS) received a complete response letter (CRL) from the U.S.

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar ↗

March 09, 2022

Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022 ↗

March 07, 2022

Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics...

Via Benzinga

Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices ↗

February 18, 2022

Coherus BioSciences Inc's (NASDAQ: CHRS) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.